[ad_1]
LUXEMBOURG – (COMMERCIAL THREAD) – Regulatory news:
Eurofins (Paris: ERF):
Easy, reliable, high-quality and cost-effective testing for SARS-CoV-2 (COVID-19), in accordance with local regulatory requirements, is essential to enable millions of passengers to travel in comfort and safety . Eurofins quickly developed a large network of around 500 test centers across Europe and intends to have around 1,000 test centers established by early July.
Eurofins’ network of test centers covers major travel centers and provides accessibility to testing in a wide variety of locations such as supermarkets, business parks and residential areas, thus improving proximity to customers and ease of testing.
Eurofins also operates mobile test centers to further increase availability and access. Such mobile facilities can be used by city authorities to reduce pressure on existing test centers by rapidly increasing sampling capacity. These mobile collection centers can each process up to 200 PCR tests per day. Eurofins has already launched this service in Belgium, France and Germany.
Additionally, to further support testing, especially for travel to Europe this summer, Eurofins has created an intuitive web portal for travelers to make testing appointments and access their test information, not only in their country of origin, but also in the places of destination. All Eurofins test centers are listed on a single landing page, identifying nearby test sites. This portal is available in 12 languages; https://www.eurofins.com/covid19-travel-regulations-testing-stations/
Eurofins is committed to providing the best possible testing services to all travelers looking for a smooth, comfortable and safe travel experience. Eurofins has also invested in laboratory capacity and IT solutions that will ensure fast turnaround times for test results (just a few hours from receipt of sample to the laboratory for baseline PCR tests). Along with Eurofins’ home testing offering (when supported by health authorities), the Group’s extensive test centers and mobile sampling facilities allow Eurofins to offer a simple and comprehensive experience. to international travelers across Europe and the world.
About Eurofins – the world leader in bioanalysis
Eurofins tests for life. Eurofins is the world leader in food, environmental, pharmaceutical and cosmetic product testing and contract research organization services in agroscience. Eurofins is a market leader in certain test and laboratory services for genomics, discovery pharmacology, forensics, advanced materials science and clinical study support, as well as an emerging global presence in contract development and manufacturing organizations. The Group also has a rapidly developing presence in highly specialized and molecular clinical diagnostic tests and in vitro diagnostic products.
With more than 50,000 employees through a decentralized and entrepreneurial network of more than 800 laboratories in more than 50 countries, Eurofins offers a portfolio of more than 200,000 analytical methods to assess security, identity, composition, authenticity , origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in vitro diagnostic products.
The Group’s objective is to provide its customers with high quality services, innovative solutions and precise results on time. Eurofins is ideally positioned to support the increasingly stringent quality and safety standards of its customers and the increasing demands of regulatory authorities as well as the demands of healthcare professionals around the world.
In 2020, Eurofins reacted swiftly to meet the global challenge of COVID-19, creating the capacity to help more than 20 million patients each month who may have been affected by the pandemic with our test products and services and by directly supporting healthcare professionals working on the front line to fight the virus. The Group has set up extensive PCR testing capacities and carried out more than 25 million tests in its own laboratories, supports the development of a certain number of vaccines and has set up its testing, surveillance and monitoring programs. SAFER @ WORK â„¢ advice to help ensure safer environments during COVID-19[FEMININE.
Eurofins has experienced very strong growth since its creation and its strategy is to continue to expand its technological portfolio and its geographic reach. Through R&D and acquisitions, the Group relies on the latest developments in biotechnology and analytical chemistry to offer its customers unique analytical solutions.
Eurofins Scientific shares are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).
As long as it has not been legally made public by Eurofins via approved distribution channels, this document contains inside information for the purposes of Regulation (EU) 596/2014 of the European Parliament and of the Council of April 16, 2014 on abuses market, as amended.
Important Disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained in this document represent the judgment of the management of Eurofins Scientific as of the date of this press release. These forward-looking statements are not guarantees of future performance, and the forward-looking events described in this press release may not occur. Eurofins Scientific disclaims any intention or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made on the basis of the information available to the management of the Company at the date of publication, but no guarantee can be given as to their completeness or validity.
[ad_2]
